Safety and Tolerability of Fingolimod in Latin American Patients with Relapsing-Remitting Multiple Sclerosis: The Open-Label FIRST LATAM Study

Efficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses

(2014) Angel R. Chinea Martinez et al.   ADVANCES IN THERAPY

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis

(2014) Yara Dadalti Fragoso et al.   ARQUIVOS DE NEURO-PSIQUIATRIA

Management of relapsing–remitting multiple sclerosis in Latin America: Practical recommendations for treatment optimization

(2014) Jorge Correale et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

(2013) Ralf Gold et al.   JOURNAL OF NEUROLOGY

Prevalence and clinical features of multiple sclerosis in Latin America

(2012) Ernesto Ojeda et al.   CLINICAL NEUROLOGY AND NEUROSURGERY

Multiple sclerosis in Hispanics: a study of clinical disease expression

(2011) L Amezcua et al.   Multiple Sclerosis Journal

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE